Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Mader, Emily K ^a   Butler, Greg ^a   Dowdy, Sean C ^a   Mariani, Andrea ^a   Knutson, Keith L ^b   Federspiel, Mark J ^a   Russell, Stephen J ^a   Galanis, Evanthia ^a   Dietz, Allan B ^a   Peng, Kah Whye ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Efficacy; Mesenchymal stem cell; Optimization; Ovarian cancer; Safety; Virotherapy

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; CELL HOMING; CHEMOTAXIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; KARYOTYPING; MEASLES VACCINATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL; PHENOTYPIC VARIATION; PROCESS OPTIMIZATION; RECURRENT CANCER; TRISOMY; TRISOMY 20; VIRUS IMMUNITY;

ANIMALS; CASE-CONTROL STUDIES; FEASIBILITY STUDIES; FEMALE; HUMANS; KARYOTYPING; MEASLES VIRUS; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; MICE, SCID; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84872681869     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-20     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Markman M. Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward. Nat Rev Clin Oncol 2012, 9:69-70.
3. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011, 71:1397-1412. 10.2165/11591720-000000000-00000, 21812505.
4. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006, 107:77-85. 10.1097/01.AOG.0000192407.04428.bb, 16394043.
5. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012, 12:383-396. 10.1038/nri3209, 22531326.
6. Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med 2011, 9:52. 10.1186/1741-7015-9-52, 3098796, 21569277.
7. Myers TJ, Granero-Molto F, Longobardi L, Li T, Yan Y, Spagnoli A. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther 2010, 10:1663-1679. 10.1517/14712598.2010.531257, 3057936, 21058931.
8. Dwyer RM, Kerin MJ. Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?. Hum Gene Ther 2010, 21:1506-1512. 10.1089/hum.2010.135, 20649487.
9. Russell SJ, Peng KW. The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther 2008, 10:380-386.
10. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012, 30:658-670. 10.1038/nbt.2287, 22781695.
11. Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther 2011, 18:305-317. 10.1038/cgt.2011.7, 21436867.
12. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010, 6:941-949. 10.2217/fon.10.66, 20528232.
13. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Molecular therapy: the journal of the American Society of Gene Therapy 2010, 18:251-263.
14. Dingli D, Bergert ER, Bajzer Z, O'Connor MK, Russell SJ, Morris JC. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun 2004, 325:157-166. 10.1016/j.bbrc.2004.09.219, 15522214.
15. Wildner O, Morris JC, Vahanian NN, Ford H, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999, 6:57-62. 10.1038/sj.gt.3300810, 10341876.
16. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009, 330:213-241. 10.1007/978-3-540-70617-5_11, 19203112.
17. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010, 17:550-558. 10.1038/cgt.2010.10, 2907639, 20379224.
18. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003, 63:2462-2469.
19. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002, 62:4656-4662.
20. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001, 98:2002-2007. 10.1182/blood.V98.7.2002, 11567982.
21. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009, 11:43-53. 2717625, 19169959.
22. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007, 82:700-710. 10.1038/sj.clpt.6100409, 2769566, 17971816.
23. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ, Aderca I, Zollman PJ, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010, 70:875-882. 10.1158/0008-5472.CAN-09-2762, 2890216, 20103634.
24. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 2004, 93:699-701. 10.1016/j.ygyno.2004.03.023, 15196867.
25. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clinical cancer research: an official journal of the American Association for Cancer Research 2006, 12:1868-1875.
26. Thorne SH, Contag CH. Combining immune cell and viral therapy for the treatment of cancer. Cellular and molecular life sciences: CMLS 2007, 64:1449-1451. 10.1007/s00018-007-6550-z, 17404689.
27. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Molecular therapy: the journal of the American Society of Gene Therapy 2007, 15:660-665.
28. Nakashima H, Kaur B, Chiocca EA. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev 2010, 21:119-126. 10.1016/j.cytogfr.2010.02.004, 3109423, 20226717.
29. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 2010, 17:289-297. 10.1038/cgt.2009.67, 19876078.
30. Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm 2011, 8:1559-1572. 10.1021/mp200161f, 3185211, 21718006.
31. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006, 5:755-766. 10.1158/1535-7163.MCT-05-0334, 16546991.
32. Dittmar T, Entschladen F. Migratory Properties of Mesenchymal Stem Cells. Adv Biochem Eng Biotechnol 2012,
33. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15:7246-7255.
34. Crespo-Diaz R, Behfar A, Butler GW, Padley DJ, Sarr MG, Bartunek J, Dietz AB, Terzic A. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant 2011, 20:797-811. 10.3727/096368910X543376, 21092406.
35. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003, 24:48-77. 10.1210/er.2001-0029, 12588808.
36. Lech PJ, Russell SJ. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines 2010, 9:1275-1302. 10.1586/erv.10.124, 21087107.
37. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002, 8:527-531. 10.1038/nm0502-527, 11984600.
38. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007, 14:324-333. 10.1038/sj.gt.3302880, 17051248.
39. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 2009, 84:401-407. 10.1002/ajh.21444, 2805200, 19507209.
40. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010, 28:1099-1106. 10.1002/stem.430, 20506226.
41. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67:1187-1194. 10.1001/archneurol.2010.248, 3036569, 20937945.
42. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286. 10.1016/j.jacc.2009.06.055, 19958962.
43. Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011, 20:1297-1308. 10.1089/scd.2010.0466, 21303266.
44. Willis MJ, Bird LM, Dell'Aquilla M, Jones MC. Expanding the phenotype of mosaic trisomy 20. Am J Med Genet A 2008, 146:330-336.
45. Lechner JF, Neft RE, Gilliland FD, Crowell RE, Auckley DH, Temes RT, Belinsky SA. Individuals at high risk for lung cancer have airway epithelial cells with chromosome aberrations frequently found in lung tumor cells. In Vivo 1998, 12:23-26.
46. Lee JM. The role of protein elongation factor eEF1A2 in ovarian cancer. Reproductive biology and endocrinology: RB&E 2003, 1:69.
47. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 2000, 6:1833-1839.
48. Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol 2012, 797:97-109. 10.1007/978-1-61779-340-0_8, 21948472.
49. Thaci B, Ahmed AU, Ulasov IV, Tobias AL, Han Y, Aboody KS, Lesniak MS. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther 2012, 19:431-442. 10.1038/cgt.2012.21, 3356460, 22555507.
50. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311:1780-1784. 10.1126/science.1121411, 16556847.
51. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL, Russell SJ. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther 2001, 8:1456-1463. 10.1038/sj.gt.3301552, 11593358.